<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230593</url>
  </required_header>
  <id_info>
    <org_study_id>10-469</org_study_id>
    <nct_id>NCT01230593</nct_id>
  </id_info>
  <brief_title>Chalazion Conservative Treatment Trial</brief_title>
  <official_title>A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edward-Elmhurst Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the
      blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a
      typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The
      chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute
      to its morbidity. There are many anecdotal first line treatments for this condition,
      including warm compresses to the eyelid, topical antibiotics, topical steroids, topical
      combination antibiotic/steroid, and oral antibiotics. There have been no clinical trials to
      compare the efficacy of any of these conservative treatments. We wish to determine the most
      effective conservative medical treatment for chalazia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete resolution</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>Defined as chalazion size regression of 100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chalazion Size Difference Post-Treatment</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>Change of size of eyelid chalazion in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent chalazion size improvement</measure>
    <time_frame>4-6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Chalazion Unspecified Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Left Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Right Eye, Unspecified Eyelid</condition>
  <condition>Chalazion Both Eyes</condition>
  <arm_group>
    <arm_group_label>Hot Compress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the hot compress arm will be shown how to apply hot compresses to the affected lid and gently massage the lid to encourage the chalazion to spontaneously drain for 5 minutes, 3x/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobrex Drops and Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Tobrex arm will be prescribed Tobrex drops 3x/day and ointment to be applied before bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobradex Drops and Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Tobradex arm will be prescribed Tobradex drops 3x/day and ointment to be applied before bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobrex Drops and Ointment</intervention_name>
    <description>Tobrex drops will be given to the affected eye 3x/day, and Tobrex ointment will be given at night before bed.</description>
    <arm_group_label>Tobrex Drops and Ointment</arm_group_label>
    <other_name>Aktob</other_name>
    <other_name>Tobralcon</other_name>
    <other_name>Tobrasol</other_name>
    <other_name>Tobramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobradex Drops and Ointment</intervention_name>
    <description>Tobradex drops will be given to the affected eye 3x/day, and Tobradex ointment will be given at night before bed.</description>
    <arm_group_label>Tobradex Drops and Ointment</arm_group_label>
    <other_name>Tobramycin/dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot Compresses</intervention_name>
    <description>Hot compresses 3x/day to eyelids</description>
    <arm_group_label>Hot Compress</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients age 18 and above

          -  Patient with a palpable chalazion on any eyelid

          -  Patients with multiple chalazia but only a single one on each lid

          -  Normal lid anatomy enabling lid eversion

        Exclusion Criteria

          -  Patients with chalazia with atypical features (recurring chalazion, abnormal
             surrounding lid tissue, associated loss of lashes) that may indicate suspicion of
             malignancy

          -  Patients allergic to any agents being used in the study (tobramycin, dexamethasone)

          -  Patients who have had previous eyelid surgery to the same eyelid as the chalazion

          -  Patients under 18 years of age

          -  Patients without palpable lid chalazion

          -  Patients with multiple chalazia on one eyelid

          -  Patients with concurrent eyelid infection (cellulitis or conjunctivitis)

          -  Patients unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Y Wu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elmhurst Hospital Center</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Eye Clinic</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Albert Wu</investigator_full_name>
    <investigator_title>M.D. Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 4, 2017</submitted>
    <returned>May 11, 2017</returned>
    <submitted>April 2, 2018</submitted>
    <returned>May 2, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

